Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a medical device company, announced today the completion of a significant financial transaction involving the issuance of $700 million in notes with a 5.2% interest rate, maturing on September 15, 2034.
The notes, which will pay interest semi-annually starting March 15, 2025, provide the company with additional capital. Zimmer Biomet has reserved the right to redeem the notes before the maturity date, with the redemption price being the greater of a calculated sum of the present values of remaining payments or 100% of the principal amount, plus any accrued interest.
Furthermore, in the event of a change of control repurchase event, Zimmer Biomet is obligated to offer to repurchase the notes, providing holders with an option for liquidity. The terms also include customary events of default, which could trigger accelerated repayment obligations.
In other recent news, Zimmer Biomet has seen various developments. The company's shares have been reduced to a target of $130 from $135 by a Stifel analyst, who maintained a Buy rating.
This comes after the company's mixed performance in the second quarter of 2024, despite several positive factors including the ROSA robot contributing to growth and faster than expected restructuring initiatives.
Zimmer Biomet has also revealed plans to acquire OrthoGrid Systems, a company specializing in AI-driven surgical guidance. The acquisition is expected to close by the end of the fourth quarter of 2024 and includes OrthoGrid's flagship Hip AI system, two FDA-cleared orthopedic applications, and over 40 patents.
Moreover, the company has secured $2.5 billion in credit facilities, part of its strategy to maintain a strong liquidity position. In addition, Zimmer Biomet has announced the appointment of Devdatt "Dev" Kurdikar, the current President, CEO, and board member of Embecta Corp., to its Board of Directors.
Lastly, Zimmer Biomet has entered into a multi-year co-marketing agreement with RevelAi Health, aiming to enhance value-based orthopedic care through AI-powered solutions. These recent developments reflect Zimmer Biomet's ongoing commitment to growth and innovation.
InvestingPro Insights
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has demonstrated a strategic approach to capital management with its recent issuance of notes. This financial move aligns with the company's history of maintaining dividend payments for 13 consecutive years, which is indicative of a stable financial policy. Moreover, Zimmer Biomet's management has been actively engaging in share buybacks, showcasing confidence in the company's value. These actions are backed by a solid financial performance, with Zimmer Biomet reporting a revenue growth of 4.58% in the last twelve months as of Q2 2024, and maintaining a robust gross profit margin of 71.79%.
InvestingPro Tips reveal that while 22 analysts have revised their earnings forecasts downwards for the upcoming period, the company is still expected to be profitable this year and has been profitable over the last twelve months. Additionally, Zimmer Biomet is trading at a low P/E ratio relative to near-term earnings growth, with an adjusted P/E ratio of 17.9 and a PEG ratio of 0.22 for the same period, suggesting the stock may be undervalued given its earnings trajectory. For investors considering Zimmer Biomet, these metrics could provide a compelling case for the company's financial health and potential for growth. There are additional insights and tips available on InvestingPro, which currently lists over 6 more tips for Zimmer Biomet at https://www.investing.com/pro/ZBH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.